Sabra Healthcare REIT, Inc. (NASDAQ:SBRA) Receives Average Recommendation of “Moderate Buy” from Brokerages
Sabra Healthcare REIT (NASDAQ: SBRA) received a consensus “Moderate Buy” rating from 10 analysts, with five “hold” and five “buy” ratings, according to MarketBeat. The average 12-month target price is $22.30. Wells Fargo and UBS raised targets to $22; Citigroup to $24. SBRA reported $0.16 EPS on $211.74M revenue and paid a $0.30 quarterly dividend (6% yield).
How this was made
The 30-second read
Why it matters
For traders, the only actionable element is sentiment/expectations drift (consensus Moderate Buy; average target $22.30) rather than a fresh operational or financial datapoint.
Market read
Moderate Buy consensus and higher targets may support near-term sentiment, but the article lacks a new catalyst beyond analyst framing.
What to watch
Dividend payout ratio (~190%) and REIT leverage/interest-rate sensitivity could cap upside even if targets rise.
Background
The piece compiles consensus ratings, recent broker target adjustments, institutional ownership changes, and selected fundamentals (earnings, guidance, dividend).
Ticker impact
Consensus “Moderate Buy” and multiple broker target changes (e.g., Citi to $24) update Street expectations for Sabra Healthcare REIT.
Likely modest upward bias/mean-reversion support rather than a catalyst-driven breakout.
The article is primarily an analyst-rating/target recap; it does not report new earnings, guidance, deals, or regulatory actions beyond already-known quarterly results and FY 2026 EPS range.
Market effects
Reinforces cautious optimism toward healthcare REIT net-lease demand, but provides no sector-wide regulatory or macro shock.
None indicated.
None indicated.
Counterpoint
Analyst target hikes may already be priced; without new fundamentals, the stock may trade more on rates/credit than on rating changes.
Key entities
- companySabra Healthcare REIT, Inc.
NASDAQ-listed healthcare REIT subject of the consensus rating, target-price updates, and dividend/earnings recap.
